TY  - JOUR
AU  - Khorrami, Sam
AU  - Ginard, Daniel
AU  - Marin-Jimenez, Ignacio
AU  - Chaparro, Maria
AU  - Sierra, Monica
AU  - Aguas, Mariam
AU  - Sicilia, Beatriz
AU  - Garcia-Sanchez, Valle
AU  - Suarez, Cristina
AU  - Villoria, Albert
AU  - Taxonera, Carlos
AU  - Velasco-Guardado, Antonio
AU  - Martinez-Gonzalez, Javier
AU  - Gisbert, Javier P
PY  - 2016
DO  - 10.1097/MIB.0000000000000842
UR  - http://hdl.handle.net/10668/10181
T2  - Inflammatory bowel diseases
AB  - Ustekinumab is a fully human monoclonal antibody against IL-12/23. Ustekinumab induced clinical response and maintained higher rate of response than placebo in patients with Crohn's disease (CD). This study aims to assess the effectiveness and safety...
LA  - en
PB  - Oxford University Press
KW  - Anti-inflammatory agents
KW  - Crohn disease
KW  - Cutaneous fistula
KW  - Drug administration schedule
KW  - Adult
KW  - Female
KW  - Follow-up studies
KW  - Humans
KW  - Injections, subcutaneous
KW  - Male
KW  - Middle aged
KW  - Rectal fistula
KW  - Retreatment
KW  - Retrospective studies
KW  - Spain
KW  - Ustekinumab
TI  - Ustekinumab for the Treatment of Refractory Crohn's Disease: The Spanish Experience in a Large Multicentre Open-label Cohort.
TY  - research article
VL  - 22
ER  -